In an effort to determine whether the tumor-targeting IL-4Rα-aptamer liposome–cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODN) delivery system could deliver CpG into tumors and circumvent immunosuppressive TME [71], Liu et al. discovered that when CT26 tumor-bearing mice were treated with IL-4Rα-liposome-CpG therapy, the anti-tumor activity was significantly higher than in the group used as a control [72]. Here, IL4R is linked to neoplasm.